symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
BVXV,1.36,2.366182,38939,4966625,0,0.63-11.49,0.01,BiondVax Pharmaceuticals Ltd.,USD,0001611747,US09073Q1058,09073Q105,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.biondvax.com,"BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center GÃ¶ttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.","Mr. Amir  Reichman M.B.A., M.Sc.",Healthcare,IL,33,972 8 930 2529,Jerusalem BioPark Building,Jerusalem,,,0.502726,1.57273,https://financialmodelingprep.com/image-stock/BVXV.png,2015-05-12,False,False,False,True,False
